SecBot SecBot
SECBOTREPLAY Home › Report › LYEL

LYEL · Insiders buy $50M, sell $19K

Lyell Immunopharma, Inc. · CLUSTER filed Nov 12, 2026 at 16:13 ET

At the news

BULLISHIMPACT 6/10

CLUSTER filed Nov 12, 2026 at 16:13 ET

Two 10% owner affiliates of ARCH Venture Partners purchased $50M in open-market shares on November 4, 2026, while three executives sold a combined $19K in open-market sales on November 10, 2026. The insider buying follows Lyell's Q3 2026 earnings release on November 4, which highlighted strong ronde-cel clinical data and an $80M private placement extending cash runway into 2028.

  • ARCH Venture Partners IX and ARCH Venture Fund XIII each purchased 2.32M shares at $10.77, totaling $50M in open-market buys on November 4, 2026.
  • Three executives sold a combined $18,765 in open-market sales on November 10, 2026, at $15.93 per share.
  • The insider buying occurred on the same day as Lyell's Q3 2026 earnings release, which reported a GAAP net loss of $45.5M but highlighted strong ronde-cel clinical data and an $80M private placement.
  • The $50M insider purchase represents approximately 12.1% of Lyell's $412M market cap, a highly material signal.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access